JP2000507961A - Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療 - Google Patents

Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療

Info

Publication number
JP2000507961A
JP2000507961A JP10528575A JP52857598A JP2000507961A JP 2000507961 A JP2000507961 A JP 2000507961A JP 10528575 A JP10528575 A JP 10528575A JP 52857598 A JP52857598 A JP 52857598A JP 2000507961 A JP2000507961 A JP 2000507961A
Authority
JP
Japan
Prior art keywords
alkylene
mono
alkyl
optionally
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP10528575A
Other languages
English (en)
Japanese (ja)
Inventor
キャメロン，キンバリー・オーキーフェ
ケ，フア・チュー
レフカー，ブルース・アレン
ロサティ，ロバート・ルイス
トンプソン，デーヴィッド・デュアン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2000507961A publication Critical patent/JP2000507961A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP10528575A 1996-12-20 1997-11-27 Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療 Withdrawn JP2000507961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3356996P 1996-12-20 1996-12-20
US60/033,569 1996-12-20
PCT/IB1997/001483 WO1998027976A1 (en) 1996-12-20 1997-11-27 Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006141297A Division JP2006290895A (ja) 1996-12-20 2006-05-22 Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療

Publications (1)

Publication Number Publication Date
JP2000507961A true JP2000507961A (ja) 2000-06-27

Family

ID=21871174

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10528575A Withdrawn JP2000507961A (ja) 1996-12-20 1997-11-27 Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療
JP2006141297A Pending JP2006290895A (ja) 1996-12-20 2006-05-22 Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006141297A Pending JP2006290895A (ja) 1996-12-20 2006-05-22 Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療

Country Status (19)

Country Link
US (1) US6426359B1 (da)
EP (1) EP0951282B1 (da)
JP (2) JP2000507961A (da)
KR (1) KR100359557B1 (da)
AT (1) ATE390917T1 (da)
AU (1) AU4881697A (da)
CA (1) CA2275595C (da)
CY (1) CY2610B2 (da)
DE (1) DE69738613T2 (da)
DK (1) DK0951282T3 (da)
ES (1) ES2303341T3 (da)
HU (1) HUP0001836A3 (da)
IL (2) IL130333A0 (da)
MY (1) MY132818A (da)
NZ (1) NZ335770A (da)
PT (1) PT951282E (da)
TW (1) TW562677B (da)
WO (1) WO1998027976A1 (da)
ZA (1) ZA9711435B (da)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002104939A (ja) * 2000-07-28 2002-04-10 L'oreal Sa 頭髪及び他の体毛の喪失を低下させ、減少させ又は停止させるための化粧品としての、プロスタグランジンｅｐ−２及び／又はｅｐ−４受容体の非−プロスタグランジン系アゴニストの使用
JP2002121118A (ja) * 2000-07-28 2002-04-23 L'oreal Sa 頭髪及び他の体毛の喪失を低下させ、減少させ又は停止させるための化粧品としての、プロスタグランジンｅｐ−３受容体アンタゴニストの使用
WO2005009468A1 (ja) * 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027976A1 (en) 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
EP1000619A3 (en) * 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
AU9756898A (en) * 1998-11-12 2000-06-05 Gemini Genomics Ab Human prostaglandin receptors and methods of use thereof
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
BR0015781A (pt) * 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
PL356662A1 (en) * 1999-12-22 2004-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
KR20040063981A (ko) * 2001-11-30 2004-07-15 화이자 프로덕츠 인크. Ｅｐ2 수용체 선택성 작용제를 포함하는 제약 조성물 및투여 방법
WO2004073591A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
JP2006519250A (ja) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるｅｐ２選択的受容体アゴニストの使用
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
ATE465986T1 (de) 2005-01-14 2010-05-15 Allergan Inc Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
US8080567B2 (en) 2005-08-09 2011-12-20 Asterand Uk Limited EP2 receptor agonists
US7323591B2 (en) * 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
WO2009065081A2 (en) * 2007-11-14 2009-05-22 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
US8592413B2 (en) * 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4033996A (en) * 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4112236A (en) * 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
AU615534B2 (en) 1988-04-19 1991-10-03 Teijin Limited 2-substituted-2-cyclopentenones
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
WO1998027976A1 (en) 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002104939A (ja) * 2000-07-28 2002-04-10 L'oreal Sa 頭髪及び他の体毛の喪失を低下させ、減少させ又は停止させるための化粧品としての、プロスタグランジンｅｐ−２及び／又はｅｐ−４受容体の非−プロスタグランジン系アゴニストの使用
JP2002121118A (ja) * 2000-07-28 2002-04-23 L'oreal Sa 頭髪及び他の体毛の喪失を低下させ、減少させ又は停止させるための化粧品としての、プロスタグランジンｅｐ−３受容体アンタゴニストの使用
WO2005009468A1 (ja) * 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤

Also Published As

Publication number Publication date
KR100359557B1 (ko) 2002-11-08
PT951282E (pt) 2008-06-09
HUP0001836A2 (hu) 2000-09-28
ES2303341T3 (es) 2008-08-01
IL130333A0 (en) 2000-06-01
EP0951282A1 (en) 1999-10-27
IL130333A (en) 2007-02-11
WO1998027976A1 (en) 1998-07-02
DE69738613T2 (de) 2009-04-30
AU4881697A (en) 1998-07-17
HUP0001836A3 (en) 2001-05-28
CY2610B2 (en) 2010-10-22
US6426359B1 (en) 2002-07-30
CA2275595C (en) 2003-08-05
ZA9711435B (en) 1999-06-21
DK0951282T3 (da) 2008-07-14
ATE390917T1 (de) 2008-04-15
JP2006290895A (ja) 2006-10-26
KR20000057680A (ko) 2000-09-25
EP0951282B1 (en) 2008-04-02
CA2275595A1 (en) 1998-07-02
DE69738613D1 (de) 2008-05-15
NZ335770A (en) 2005-01-28
MY132818A (en) 2007-10-31
TW562677B (en) 2003-11-21

Similar Documents

Publication Publication Date Title
KR100359557B1 (ko) 이피2 수용체 서브타입 선택적 프로스타글란딘 이2 작용물질을이용한 골격 질환의 예방 및 치료
JP4067105B2 (ja) ある種のプロスタグランジンアゴニストによる骨質量の減少の防止および回復
DE60005471T2 (de) EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose
US6531485B2 (en) Prostaglandin agonists
TW200424170A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
CA2334257C (en) Treatment of osteoporosis with ep2/ep4 receptor selective agonists
JPH11180926A (ja) 骨粗しょう症用化合物
JP2002308771A (ja) 骨粗鬆症のための多剤併用療法
AU764409B2 (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20051121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061017

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070730